FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma

By :

New Ebola Vaccine for Exposure Risk

Amphastar Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted approval of its New Drug Application (NDA) for Primatene Mist (epinephrine inhalation aerosol bronchodilator suspension), which is delivered by a metered dose inhaler (MDI) with a non-chlorofluorocarbon (CFC) propellant. Primatene Mist is the only FDA-approved asthma inhaler available without a prescription in the United States. Primatene Mist is indicated for the temporary relief of mild symptoms of intermittent asthma in people ages 12 and above. #FDA #Drug #Approval
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF DIC Team

Approval of new treatment for adults with partial-onset seizures

PHAF Team

Navigating the New Clozapine REMS

PHAF Team

LENVIMA (lenvatinib) capsules

PHAF Team

FDA approval : first treatment for frequent urination at night

PHAF Team

A new eczema drug Dupixent : FDA Approval

PHAF Team

New drug that can prevent breast cancer growth identified

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.